OBJECTIVES: The aim of the study was to investigate the association of adiposity with longitudinal kidney function change in 544 HIV-infected persons in the Study of Fat Redistribution and Metabolic Change in HIV infection (FRAM) cohort over 5 years of follow-up. METHODS: The regional distribution of muscle and adipose tissue was quantified by whole-body magnetic resonance imaging (MRI), and total adiponectin and leptin levels were measured in serum. Kidney function was assessed using the estimated glomerular filtration rate from serum cystatin C (eGFRCys), obtained at baseline and follow-up. Rapid kidney function decline was defined as annual loss of eGFRCys ≥ 3 mL/min/1.73 m(2) , and incident chronic kidney disease (CKD) was defined as eGFRCys <60 mL/min/1.73 m(2) . Multivariate regression analysis was adjusted for age, race, gender, glucose, antihypertensive use, serum albumin, baseline and change in HIV viral load. RESULTS: At baseline, mean age was 43 years, mean eGFRCys was 86 mL/min/1.73 m(2) , and 21% of patients had albuminuria. The mean (± standard deviation) eGFRCys decline was -0.11 ± 4.87 mL/min/1.73 m(2) per year; 23% of participants had rapid kidney function decline, and 10% developed incident CKD. The lowest tertile of visceral adipose tissue and the highest tertile of adiponectin were both marginally associated with annual kidney function decline of -0.5 mL/min/1.73 m(2) each, but these associations were not statistically significant after adjustment. We found no statistically significant associations of MRI-measured regional adiposity or serum adipokines with rapid kidney function decline or incident CKD (all P-values>0.1 in adjusted models). CONCLUSIONS: Contrary to findings in the general population, adiposity did not have a substantial association with longitudinal change in kidney function among HIV-infected persons.
OBJECTIVES: The aim of the study was to investigate the association of adiposity with longitudinal kidney function change in 544 HIV-infectedpersons in the Study of Fat Redistribution and Metabolic Change in HIV infection (FRAM) cohort over 5 years of follow-up. METHODS: The regional distribution of muscle and adipose tissue was quantified by whole-body magnetic resonance imaging (MRI), and total adiponectin and leptin levels were measured in serum. Kidney function was assessed using the estimated glomerular filtration rate from serum cystatin C (eGFRCys), obtained at baseline and follow-up. Rapid kidney function decline was defined as annual loss of eGFRCys ≥ 3 mL/min/1.73 m(2) , and incident chronic kidney disease (CKD) was defined as eGFRCys <60 mL/min/1.73 m(2) . Multivariate regression analysis was adjusted for age, race, gender, glucose, antihypertensive use, serum albumin, baseline and change in HIV viral load. RESULTS: At baseline, mean age was 43 years, mean eGFRCys was 86 mL/min/1.73 m(2) , and 21% of patients had albuminuria. The mean (± standard deviation) eGFRCys decline was -0.11 ± 4.87 mL/min/1.73 m(2) per year; 23% of participants had rapid kidney function decline, and 10% developed incident CKD. The lowest tertile of visceral adipose tissue and the highest tertile of adiponectin were both marginally associated with annual kidney function decline of -0.5 mL/min/1.73 m(2) each, but these associations were not statistically significant after adjustment. We found no statistically significant associations of MRI-measured regional adiposity or serum adipokines with rapid kidney function decline or incident CKD (all P-values>0.1 in adjusted models). CONCLUSIONS: Contrary to findings in the general population, adiposity did not have a substantial association with longitudinal change in kidney function among HIV-infectedpersons.
Authors: Wei Shen; ZiMian Wang; Haiying Tang; Stanley Heshka; Mark Punyanitya; Shankuan Zhu; Jianbo Lei; Steven B Heymsfield Journal: Obes Res Date: 2003-02
Authors: Jordan E Lake; David Wohl; Rebecca Scherzer; Carl Grunfeld; Phyllis C Tien; Stephen Sidney; Judith S Currier Journal: AIDS Care Date: 2011-06-24
Authors: Andy Choi; Rebecca Scherzer; Peter Bacchetti; Phyllis C Tien; Michael S Saag; Cynthia L Gibert; Lynda A Szczech; Carl Grunfeld; Michael G Shlipak Journal: Am J Kidney Dis Date: 2010-08-14 Impact factor: 8.860
Authors: Ian H de Boer; Ronit Katz; Linda F Fried; Joachim H Ix; Jose Luchsinger; Mark J Sarnak; Michael G Shlipak; David S Siscovick; Bryan Kestenbaum Journal: Am J Kidney Dis Date: 2009-09-25 Impact factor: 8.860
Authors: Caroline S Fox; Martin G Larson; Eric P Leip; Bruce Culleton; Peter W F Wilson; Daniel Levy Journal: JAMA Date: 2004-02-18 Impact factor: 56.272
Authors: Chris T Longenecker; Rebecca Scherzer; Peter Bacchetti; Cora E Lewis; Carl Grunfeld; Michael G Shlipak Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: R V Considine; M K Sinha; M L Heiman; A Kriauciunas; T W Stephens; M R Nyce; J P Ohannesian; C C Marco; L J McKee; T L Bauer Journal: N Engl J Med Date: 1996-02-01 Impact factor: 91.245
Authors: Phyllis C Tien; Constance Benson; Andrew R Zolopa; Stephen Sidney; Dennis Osmond; Carl Grunfeld Journal: Am J Epidemiol Date: 2006-03-08 Impact factor: 4.897
Authors: Yassine Bouatou; Angele Gayet Ageron; Enos Bernasconi; Manuel Battegay; Matthias Hoffmann; Cornelia Staehelin; Laurent Merz; Helen Kovari; Christoph Fux; Sophie de Seigneux; Alexandra Calmy Journal: Kidney Int Rep Date: 2018-05-08